Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Join our webinar to discover the Real World Data needed to generate evidence and answer critical research questions. Gain insights into healthcare systems and unique datasets from North America, Europe, Asia Pacific, and Latin America to understand healthcare trends, treatment approaches, and market dynamics.
Register Free: https://www.pharmexec.com/pe_w/real-world-data-tour
Event Overview:
Calling all Real World Data researchers! Missed the Global Health Data Passport Webinar Series?
Join this webinar to take a data landscape world tour of the 2024 series highlights. Explore unique datasets from each region, covering key therapeutic areas, to gain faster insights into healthcare trends, treatment approaches, and market dynamics. Discover the Real World Data sources you need to generate evidence and answer critical research questions.
Three key take-aways
Speakers
Megan Califano
Director, Offering Management
IQVIA USA
Alan Thomas
Senior Director, Strategic Planning
IQVIA Japan
Paul Berg
Senior Principal, Real World Solutions
IQVIA UK
Ramon Pereira
Head of Data Science
IQVIA Brazil & LATAM
Ken Chin
Senior Consultant
IQVIA Australia
Long Pang
Engagement Manager
Real World Solutions, IQVIA
China
Andrzej Mazurek
Engagement Manager
IQVIA Poland
Sarah Seager
Senior Director, Analytics & AI
IQVIA Global
Register Free: https://www.pharmexec.com/pe_w/real-world-data-tour
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Bristol Myers Squibb’s Cobenfy Falls Short in Phase III Trial as Add On Therapy for Schizophrenia
April 23rd 2025In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with inadequately controlled schizophrenia did not achieve statistically significant improvements.